Your session is about to expire
← Back to Search
Olaparib for Ovarian and Peritoneal Cancer
Study Summary
This trial is testing olaparib to see if it can stop the growth of cancer cells in patients with BRCA-mutant ovarian, primary peritoneal, or fallopian cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your liver enzyme levels must be within a certain range, unless you have cancer that has spread to the liver.Your bilirubin level in the blood is not more than 1.5 times the normal limit.My cancer is either mucinous or a low-grade epithelial type.I have received treatment for ovarian, fallopian tube, or peritoneal cancer.I am not able to participate in the study's surveys because I do not speak English.You have had a bad reaction to olaparib or any of the ingredients in it.I am set to start chemotherapy before surgery to shrink my tumor after 3 cycles.Your resting ECG shows uncontrolled heart problems that can possibly be fixed.I have had cancer spread to the lining of my brain and spinal cord.I have not received a whole blood transfusion in the last 4 months.I have brain metastases that need treatment.I don't have lasting side effects from cancer treatment, except for hair loss.Your white blood cell count is higher than 1500 per mm3.You have a disease that can be measured or evaluated according to specific guidelines.I have had a bone marrow or cord blood transplant in the past.I am fully active or can carry out light work.My cancer is a high-grade type that started in my ovaries, peritoneum, or fallopian tubes and is not mucinous.I am not taking strong or moderate CYP3A inhibitor medications.I have had cancer before, but it was either treated over 5 years ago, was a non-melanoma skin cancer, or was a localized cancer that did not spread.My kidney function, measured by creatinine clearance, is adequate.I have never been treated with a PARP inhibitor like olaparib.I had major surgery more than 2 weeks ago and have recovered from it.I do not have any severe illnesses or conditions that are not under control.Your hemoglobin level should be 10.0 grams per deciliter or higher, and you shouldn't have had a blood transfusion in the past 28 days.I cannot swallow pills or have a stomach condition that affects medication absorption.I am not taking any strong or moderate drugs that affect liver enzymes.You are expected to live for at least 16 weeks.I have been diagnosed with MDS/AML or show signs of it.I have little to no nerve damage from previous treatments.I have seizures that are not controlled by medication.Your platelet count is at least 100,000 per mm3.My cancer has a BRCA mutation.
- Group 1: Treatment (olaparib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the main indications for Olaparib administration?
"Olaparib is a common prescription for advance directives, but it can also provide relief to those with malignant neoplasms of the ovaries and primary peritoneal cancers in addition to somatic delusions."
How many individuals have participated in the trial thus far?
"Affirmative. Data hosted on clinicaltrials.gov reveals that this medical trial is presently recruiting participants, which was published to the platform on June 7th 2019 and revised most recently in May 27th 2022. Seventeen patients are sought out from one centre alone."
Has Olaparib been evaluated in any additional trials?
"Currently, 188 investigations into Olaparib are taking place. 27 of these clinical trials have reached Phase 3. There is a high concentration of studies based in Houston, Texas; however other locations around the world house 9255 active Olaparib research sites."
Are there any vacancies left for participants in this research trial?
"Affirmative, information on clinicaltrials.gov suggests that enrollment is still open for this study. It was first posted on June 7th 2019 and recently updated May 27th 2022; 17 participants are needed from a single research site."
Does this research endeavor introduce any new techniques?
"Olaparib has gone through a series of trials since its initial clinical study in 2005, sponsored by AstraZeneca. Subsequently receiving Phase 1 approval after the first trial with 98 participants, there are now 188 live medical studies for Olaparib being conducted globally across 1469 cities and60 nations."
Share this study with friends
Copy Link
Messenger